摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4,8-二氯喹啉 | 21617-12-9

中文名称
4,8-二氯喹啉
中文别名
——
英文名称
4,8-dichloroquinoline
英文别名
4,8-dichloro-quinoline;4,8-Dichlor-chinolin;4,8 dichloroquinoline;8-Chlor-4-chlorchinolin;4,8-Dichlorchinolin
4,8-二氯喹啉化学式
CAS
21617-12-9
化学式
C9H5Cl2N
mdl
MFCD00024008
分子量
198.051
InChiKey
SDPCOMBBZFETLG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    156-160 °C (lit.)
  • 沸点:
    292.9±20.0 °C(Predicted)
  • 密度:
    1.407±0.06 g/cm3(Predicted)
  • 溶解度:
    可溶于氯仿(少许)、DMSO(少许)
  • 稳定性/保质期:
    按规定使用和贮存的不会分解,避氧化剂。

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    12.9
  • 氢给体数:
    0
  • 氢受体数:
    1

安全信息

  • 危险品标志:
    Xi
  • 安全说明:
    S26,S36
  • 危险类别码:
    R36/37/38
  • WGK Germany:
    3
  • 危险品运输编号:
    NONH for all modes of transport
  • 危险标志:
    GHS07
  • 危险性描述:
    H315,H319,H335
  • 危险性防范说明:
    P261,P305 + P351 + P338

SDS

SDS:dcfe84870b6c9dc1f32b1d9aaf2778b2
查看

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 4,8-Dichloroquinoline
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 21617-12-9


SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Skin irritation (Category 2), H315
Eye irritation (Category 2), H319
Specific target organ toxicity - single exposure (Category 3), H335
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xi Irritant R36/37/38
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
Causes skin irritation.
Causes serious eye irritation.
May cause respiratory irritation.
Precautionary statement(s)
Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Other hazards - none

SECTION 3: Composition/information on ingredients
Substances
Chemical characterization : Natural product
Formula : C9H5Cl2N
Molecular Weight : 198,05 g/mol
CAS-No. : 21617-12-9
EC-No. : 244-480-1
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
4,8-Dichloroquinoline
CAS-No. 21617-12-9 Skin Irrit. 2; Eye Irrit. 2; STOT <= 100 %
EC-No. 244-480-1 SE 3; H315, H319, H335
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
4,8-Dichloroquinoline
CAS-No. 21617-12-9 Xi, R36/37/38 <= 100 %
EC-No. 244-480-1
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx), Hydrogen chloride gas
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Full contact
Material: Nitrile rubber
Minimum layer thickness: 0,11 mm
Break through time: 480 min
Splash contact
Material: Nitrile rubber
Minimum layer thickness: 0,11 mm
Break through time: 480 min
test method: EN374
If used in solution, or mixed with other substances, and under conditions which differ from EN 374,
contact the supplier of the CE approved gloves. This recommendation is advisory only and must
be evaluated by an industrial hygienist and safety officer familiar with the specific situation of
anticipated use by our customers. It should not be construed as offering an approval for any
specific use scenario.
Body Protection
impervious clothing, The type of protective equipment must be selected according to the
concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 156 - 160 °C - lit.
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4,8-二氯喹啉 在 sodium hydride 作用下, 以 四氢呋喃 为溶剂, 反应 0.5h, 生成 4-(8-chloro-quinolin-4-yloxy)-piperidine-1-carboxylic acid isopropyl ester
    参考文献:
    名称:
    [EN] FUSED-ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO
    [FR] DERIVES ARYLE ET HETEROARYLE CONDENSES UTILISES COMME MODULATEURS DU METABOLISME ET PROPHYLAXIE ET TRAITEMENT DES TROUBLES METABOLIQUES
    摘要:
    公开号:
    WO2005007658A3
  • 作为产物:
    参考文献:
    名称:
    Synthesis of ring-substituted 4-aminoquinolines and evaluation of their antimalarial activities
    摘要:
    A simple two-step synthesis method was used to make 51 B-ring-substituted 4-hydroxyquinolines allowing analysis of the effect of ring substitutions on inhibition of growth of chloroquine sensitive and resistant strains of Plasmodium falciparum, the dominant cause of malaria morbidity. Substituted quinoline rings other than the 7-chloroquinoline ring found in chloroquine were found to have significant activity against the drug-resistant strain of P. falciparum W2. (C) 2004 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2004.12.037
点击查看最新优质反应信息

文献信息

  • Antimalarials: Synthesis of 4-aminoquinolines that circumvent drug resistance in malaria parasites
    作者:Dibyendu De、Larry D. Byers、Donald J. Krogstad
    DOI:10.1002/jhet.5570340149
    日期:1997.1
    substitution with neat amine rather than in phenol, regioselective reductive alkylation to convert the terminal primary amine (12a–20a) on the diaminoalkane side chain to a diethylamino group, and purification by column chromatography with basic alumina. The 1H nmr spectra obtained after regioselective reductive alkylation with sodium borodeuteride (in comparison with sodium borohydride) demonstrated that
    此处描述的策略已允许合成一系列4-氨基喹啉抗疟药。对先前合成方法的实质性改进包括用纯胺而不是苯酚进行亲核取代,区域选择性还原烷基化以将二氨基烷烃侧链上的末端伯胺(12a-20a)转化为二乙氨基,以及通过使用碱性氧化铝的柱色谱法进行纯化。用硼氘化钠(与硼氢化钠相比)进行区域选择性还原烷基化后获得的1 H nmr光谱表明,该还原烷基化是通过形成并随后原位还原相应的二酰胺而进行的。
  • Novel derivatives of 2-(4-quinolinylamino)-5-fluoro-benzoic acids
    申请人:Roussel Uclaf
    公开号:US04233305A1
    公开(公告)日:1980-11-11
    Derivatives of 2-(4-quinolinylamino)-5-fluorobenzoic acid compounds of the formula ##STR1## wherein X is selected from the group consisting of chlorine and --CF.sub.3 in the 7- or 8-position and R is selected from the group consisting of hydrogen, an esterifying group, alkali metals, alkaline earth metals, ammonium and non-toxic, pharmaceutically acceptable organic amines and their non-toxic, pharmaceutically acceptable acid addition salts having remarkable analgesic properties and their preparation.
    2-(4-喹啉基氨基)-5-氟苯甲酸化合物的衍生物的公式为##STR1##其中X选自氯和--CF.sub.3的7-或8-位,R选自氢、酯化基团、碱金属、碱土金属、铵和非毒性、药用上可接受的有机胺及其非毒性、药用上可接受的酸盐具有显著的镇痛特性及其制备。
  • Potent and Selective Inhibitors of Platelet-Derived Growth Factor Receptor Phosphorylation. 3. Replacement of Quinazoline Moiety and Improvement of Metabolic Polymorphism of 4-[4-(<i>N</i>-Substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline Derivatives
    作者:Kenji Matsuno、Junko Ushiki、Takashi Seishi、Michio Ichimura、Neill A. Giese、Jin-Chen Yu、Shusuke Takahashi、Shoji Oda、Yuji Nomoto
    DOI:10.1021/jm020505v
    日期:2003.11.1
    10 microM). Regarding replacements of quinazoline by other heterocyclic rings, pyrazolo[3,4-d]pyrimidine (39a, IC(50) = 0.17 microM) and quinoline (IC(50) of 40a is 0.18 microM; IC(50) of 40b is 0.09 microM) derivatives showed potent activity. Isoquinoline and some pyridopyrimidine derivatives were completely inactive; therefore, 1-aza has an important role. Also 7-aza and 8-aza substitution on the
    我们以前曾报道过,一系列的4- [4-(N-取代的(硫代)氨基甲酰基)-1-哌嗪基] -6,7-二甲氧基喹唑啉衍生物是有效的和选择性的血小板衍生生长因子受体(PDGFR)磷酸化抑制剂。并证明了多种生物学效应,例如通过口服给药抑制大鼠颈动脉球囊损伤后新内膜的形成。在这里,我们研究了6,7-二甲氧基喹唑啉基部分的结构活性关系。关于6,7-二甲氧基,乙氧基类似物显示出有效的活性(16b的IC(50)为0.04 microM; 17a的IC(50)为0.01 microM),烷基的进一步延伸降低了活性。有趣的是,甲氧基乙氧基(16j的IC(50)为0.02 microM; 17h的IC(50)为0.01 microM)和乙氧基乙氧基(17j的IC(50)为0。02 micro M)类似物显示出最有效的活性,表明插入的氧原子与β-PDGFR显着相互作用。在三环喹唑啉衍生物中,2-氧代咪唑并[4,5-
  • Metal‐Free Chemoselective Oxidation of 4‐Methylquinolines into Quinoline‐4‐Carbaldehydes
    作者:Jincheng Xu、Yang Li、Tianling Ding、Hao Guo
    DOI:10.1002/asia.202100704
    日期:2021.10.18
    A metal-free chemoselective oxidation of 4-methylquinolines into the corresponding aldehydes using phenyliodine(III) diacetate as the oxidant. This mild oxidation method provides an attractive alternative for synthesis of N-heteroaromatic aldehydes.
    使用二乙酸苯碘 (III) 作为氧化剂将 4-甲基喹啉无金属化学选择性氧化成相应的醛。这种温和的氧化方法为合成N-杂芳醛提供了一种有吸引力的替代方法。
  • [EN] NOVEL SUBSTITUTED INDOLES<br/>[FR] NOUVEAUX INDOLES SUBSTITUES
    申请人:ASTRAZENECA AB
    公开号:WO2003101981A1
    公开(公告)日:2003-12-11
    The present invention relates to substituted indoles of formula (I), useful as pharmaceutical compounds for treating respiratory disorders.
    本发明涉及式(I)的取代吲哚化合物,可用作治疗呼吸系统疾病的药物化合物。
查看更多